Drug Guide
Asparaginase Erwinia Chrysanthemi (recombinant)-rywn
Classification
Therapeutic: Antineoplastic agent (asparagine-specific enzyme)
Pharmacological: Enzyme, asparaginase
FDA Approved Indications
- Acute lymphoblastic leukemia (ALL) in patients who have hypersensitivity to E. coli-derived asparaginase
Mechanism of Action
Depletes circulating asparagine by catalyzing the hydrolysis of asparagine to aspartic acid and ammonia, depriving leukemia cells of an amino acid essential for their survival.
Dosage and Administration
Adult: Dose varies based on protocol; typically administered intravenously or intramuscularly under supervision.
Pediatric: Dose individualized based on body surface area or weight; administration route similar to adults.
Geriatric: No specific dosage adjustments, but monitor closely due to potential comorbidities.
Renal Impairment: Adjust as clinically indicated; no specific guidelines.
Hepatic Impairment: Use with caution; monitor liver function closely.
Pharmacokinetics
Absorption: Rapidly absorbed when given intramuscularly or intravenously.
Distribution: Widely distributed in tissues and blood.
Metabolism: Metabolized by proteolytic pathways; specific pathways not fully characterized.
Excretion: Eliminated primarily via the reticuloendothelial system; minimal renal excretion.
Half Life: Approximately 1.15 days (varies with route and individual patient factors).
Contraindications
- Hypersensitivity to E. coli-derived asparaginase or any component of the formulation.
Precautions
- Risk of allergic reactions, including anaphylaxis; monitor closely.
- Pancreatitis, coagulopathy, hepatotoxicity; monitor labs regularly.
- Use with caution in patients with bleeding disorders or hepatic impairment.
Adverse Reactions - Common
- Allergic reactions including anaphylaxis (Varies; up to 10% in some studies)
- Liver enzyme elevations (Common)
- Pancreatitis (Less common)
Adverse Reactions - Serious
- Anaphylaxis (Rare)
- Pancreatitis leading to necrosis (Rare)
- Severe hypersensitivity reactions (Rare)
- Coagulopathy or bleeding complications (Less common)
Drug-Drug Interactions
- Corticosteroids may exacerbate immunosuppression.
- Chemotherapy agents may have additive effects.
Drug-Food Interactions
N/ADrug-Herb Interactions
N/ANursing Implications
Assessment: Monitor for allergic reactions, signs of pancreatitis, liver function tests, and coagulation profiles.
Diagnoses:
- Risk for allergic reaction
- Risk for bleeding or hemorrhage
- Potential for hepatic toxicity
Implementation: Administer as prescribed, monitor vital signs, and observe for adverse reactions.
Evaluation: Assess effectiveness by reduction in leukemia cell count and monitor for adverse events.
Patient/Family Teaching
- Report any signs of allergic reactions immediately.
- Inform about possible side effects such as nausea, headache, or changes in bleeding.
- Follow storage instructions for medication.
Special Considerations
Black Box Warnings:
- Severe hypersensitivity reactions, including anaphylaxis, can occur.
- Risk of serious blood clotting and hemorrhaging.
Genetic Factors: No specific genetic markers impacting use established.
Lab Test Interference: Can cause elevations in liver function tests, coagulation parameters, and serum amylase/lipase, which should be interpreted with caution.
Overdose Management
Signs/Symptoms: Allergic reactions, hypersensitivity presenting as anaphylaxis, coagulopathy, or pancreatitis.
Treatment: Discontinue drug, provide supportive care, and manage symptoms; consider antihistamines, corticosteroids, or epinephrine for allergic reactions.
Storage and Handling
Storage: Store refrigerated at 2°C to 8°C (36°F to 46°F).
Stability: Stable under recommended storage conditions; do not freeze.